Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01719302 · ClinicalTrials.gov registry record · Phase 1

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

A Phase 1 study of Stage III Adult Soft Tissue Sarcoma, sponsored by University of Vermont.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT01719302 is a Phase 1 study of Stage III Adult Soft Tissue Sarcoma that has completed, run by University of Vermont. The registered enrollment target is 6 participants, below the 59-participant average among 5 other Stage III Adult Soft Tissue Sarcoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01719302, a Phase 1 study of Stage III Adult Soft Tissue Sarcoma, has completed, sponsored by University of Vermont.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

Chemotherapy treatment with docetaxel and gemcitabine is a standard treatment for patients with soft tissue sarcoma. This study is designed to explore whether the addition of tyrosine kinase inhibitor pazopanib enhances the anticancer effect of the chemotherapy drugs. The Phase I component of this study is designed to determine the maximum tolerated dose of pazopanib when given with docetaxel and gemcitabine. The Phase II component is designed to determine the overall response rate of the combination of docetaxel, gemcitabine and pazopanib prior to surgical resection in patients with soft tissue sarcoma.

Conditions Studied

Stage III Adult Soft Tissue Sarcoma

Interventions

  • DRUG Docetaxel
  • DRUG Gemcitabine
  • DRUG Pazopanib

Study Locations (1)

Vermont

  • Fletcher Allen Health Care - Burlington

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2012-10
Est. Completion 2015-04
Phase Phase 1

Sponsor

University of Vermont

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01719302

The ClinicalTrials.gov registry entry for NCT01719302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 5 other Stage III Adult Soft Tissue Sarcoma trials with a reported enrollment target (90% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stage III Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT01719302 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.

Frequently Asked Questions

What is clinical trial NCT01719302 about?

NCT01719302 is a clinical study titled "Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma". Chemotherapy treatment with docetaxel and gemcitabine is a standard treatment for patients with soft tissue sarcoma. This study is designed to explore whether the addition of tyrosine kinase inhibitor pazopanib enhances the anticancer effect of the chemotherapy drugs. The Phase I component of this ...

What is the current status of trial NCT01719302?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-10. Estimated completion is 2015-04.

What conditions does trial NCT01719302 study?

This clinical trial studies the following conditions: Stage III Adult Soft Tissue Sarcoma.

What interventions are being tested in trial NCT01719302?

The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), Pazopanib (DRUG).

Who is sponsoring clinical trial NCT01719302?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01719302 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage III Adult Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage III Adult Soft Tissue Sarcoma

All registered trials for this condition

Vermont

All trials with a study site in Vermont

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.